@article{4360414fa48843469a41df26df21b05a,
title = "Bleeding avoidance in transcatheter aortic valve replacement: A call to ACTion?",
keywords = "activated clotting time, bleeding, heparin, transcatheter aortic valve replacement",
author = "Tomey, {Matthew I.} and Roxana Mehran",
note = "Funding Information: Dr. Tomey has reported that he has no relationships relevant to the contents of this paper to disclose. Dr. Mehran has received institutional research grant support from The Medicines Company, Bristol-Myers Squibb, sanofi-aventis and Eli Lilly, and Daiichi Sankyo ; has received consulting fees from Abbott Vascular, AstraZeneca, Boston Scientific, Covidien, CSL Behring, Janssen Pharmaceuticals, Maya Medical, Merck & Co., Inc., Regado Biosciences, and sanofi-aventis; and has served on advisory boards for Covidien, Janssen Pharmaceuticals, and sanofi-aventis. ",
year = "2014",
month = feb,
doi = "10.1016/j.jcin.2013.11.007",
language = "English",
volume = "7",
pages = "152--153",
journal = "JACC: Cardiovascular Interventions",
issn = "1936-8798",
publisher = "Elsevier Inc.",
number = "2",
}